Literature DB >> 11526741

D1 dopamine receptors.

X Huang1, C P Lawler, M M Lewis, D E Nichols, R B Mailman.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11526741     DOI： 10.1016/s0074-7742(01)48014-7

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN： 0074-7742            Impact factor:   3.230


× No keyword cloud information.
  8 in total

1.  Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Authors:  Alia H Clark; John D McCorvy; Val J Watts; David E Nichols
Journal:  Bioorg Med Chem       Date:  2011-08-03       Impact factor: 3.641

2.  Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.

Authors:  Alia H Clark; John D McCorvy; Jason M Conley; Whitney K Williams; Markondaiah Bekkam; Val J Watts; David E Nichols
Journal:  Bioorg Med Chem       Date:  2012-09-08       Impact factor: 3.641

3.  Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues.

Authors:  Lisa A Bonner; Uros Laban; Benjamin R Chemel; Jose I Juncosa; Markus A Lill; Val J Watts; David E Nichols
Journal:  ChemMedChem       Date:  2011-04-28       Impact factor: 3.466

Review 4.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 5.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

Review 6.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012

Review 7.  Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Authors:  Robert W Buchanan; Robert Freedman; Daniel C Javitt; Anissa Abi-Dargham; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2007-07-19       Impact factor: 9.306

8.  Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Authors:  Julie A Przybyla; Juan P Cueva; Benjamin R Chemel; K Joseph Hsu; David J Riese; John D McCorvy; Julia A Chester; David E Nichols; Val J Watts
Journal:  Eur Neuropsychopharmacol       Date:  2008-11-22       Impact factor: 4.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.